Table 2. Clinical applications of ADAR in cancer treatment.

Clinical utility	Marker (give an example)	Effect	References
Therapeutic targets	GLI1	Drug 1: DYRK1A analogue	(37,38,81)
		Drug 2: targeting edited GLI1
		increased AEI
Prognostic markers	Alu editing index (AEI)		(30)
		poor prognosis
		DHFR is a target molecule of methotrexate
Predictive markers	DHFR		(43)
		Edited DHFR by ADAR1 is resistant to methotrexate in breast cancer

DYRK1A, dual specificity tyrosine-phosphorylation-regulated kinase 1A; SUFU, suppressor of fused.